Funding for this research was provided by:
Office of Extramural Research, National Institutes of Health (R01 HL132919)
Received: 30 March 2022
Accepted: 15 August 2022
First Online: 23 August 2022
: Human peripheral blood was collected from healthy volunteers who gave written consent with specific approval from the Texas A&M University human subjects review board (IRB2009-0671D). Animal experiments were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by Texas A&M University Animal Use and Care Committee (IACUC 2020-0272).
: Not applicable.
: RHG is a scientific founder of Prosia Therapies, an early stage company developing NEU3 inhibitors as therapeutics for pulmonary fibrosis. Texas A&M University has published patent applications on the use of sialidase inhibitors (United States Patent Application 20190201485) to regulate fibrosis. DP and RHG are inventors on pending patent applications for the use of sialidase inhibitors as anti-inflammatory and/or anti-obesity compounds.
: The data that support the findings of this study are available from the corresponding authors upon reasonable request.